Clinical Trials Logo

Deep Brain Stimulation clinical trials

View clinical trials related to Deep Brain Stimulation.

Filter by:

NCT ID: NCT02982512 Recruiting - Parkinson Disease Clinical Trials

Dexmedetomidine on Basal Ganglia Neuronal Activity in Parkinson's Disease

Start date: May 1, 2017
Phase: Phase 4
Study type: Interventional

The implantation of a deep brain stimulator (DBS) is an established option to improve the symptoms of Parkinson's disease (PD) in patients that do not respond adequately to medical therapy. Most centers perform this surgery using a technique that involves microelectrode recording (MER) of neuronal activity for localization of the target nucleus, microstimulation of identified targets, and neurological intraoperative testing in a cooperative patient. Dexmedetomidine, a α2-adrenergic receptors agonist, is a potent anxiolytic that acts at subcortical areas of the brain without involving GABA receptors. It provides excellent sedation without respiratory depression; also, it has an analgesic component and a predictable hemodynamic response. Low maintenance doses do not appear to interfere with MER. The possible effect of dexmedetomidine in the PD symptoms is still unclear.

NCT ID: NCT01037686 Recruiting - Parkinson's Disease Clinical Trials

The Effect of Electrode Implantation for Deep Brain Stimulation (DBS) on Brain Function Using Single Photon Emission Computed Tomography (SPECT) With Technetium-99m-ethyl Cysteinatedimer (Tc-ECD)

Start date: February 2006
Phase: N/A
Study type: Interventional

The goal of this study is to explore the effect of subthalamic nucleus (STN)-DBS surgery and stimulation in PD (Parkinson's disease) patients on regional cerebral blood (CBF) flow during cognitive task performance or at rest.